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Abstract 40 
Context: While therapy with immune checkpoint inhibitors such as nivolumab have substantially 41 
improved survival in several types of cancer, increased attention has been given to adverse 42 
immune events associated with their use, including the development of endocrine autoimmunity.  43 
Objectives: First, to describe a patient with a two-year history of metastatic small cell lung 44 
cancer who had been treated with nivolumab a few months prior to presentation with the signs 45 
and symptoms of severe hypocalcemia and hypoparathyroidism. Second, to investigate the 46 
HWLRORJ\RIWKHSDWLHQW¶Vhypoparathyroidism, including the presence of activating autoantibodies 47 
against the calcium-sensing receptor (CaSR), since humoral and cellular immune responses 48 
against the CaSR have been reported in patients with autoimmune hypoparathyroidism. 49 
Case and Results: A 61-year-old female was admitted with persistent nausea, vomiting, 50 
epigastric pain, constipation, and generalized weakness. Laboratory analyses showed low total 51 
serum calcium, ionized calcium, and parathyroid hormone (PTH). The patient was diagnosed 52 
with severe hypocalcemia as a result of autoimmune hypoparathyroidism after testing positive 53 
for CaSR-activating autoantibodies. She was treated with intravenous calcium gluconate 54 
infusions followed by a transition to oral calcium carbonate plus calcitriol which normalized her 55 
serum calcium. Her serum PTH remained low during her hospitalization and initial outpatient 56 
follow-up despite adequate repletion of magnesium.  57 
Conclusions: This case illustrates autoimmune hypoparathyroidism induced by immune 58 
checkpoint inhibitor-blockade. As immune checkpoint inhibitors are now used to treat many 59 
cancers, clinicians should be aware of the potential risk for hypocalcemia that may be 60 
associated with their use.   61 
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Introduction 62 
Immunotherapies targeting the immune checkpoint molecules, such as cytotoxic T lymphocyte 63 
antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1), and its ligand PD-L1, are now 64 
commonly used in clinical practice to treat malignancies (1). For example, nivolumab is an anti-65 
PD-1 monoclonal antibody that works as an immune checkpoint inhibitor (ICI). It blocks the 66 
interaction between PD-1 on the surface of activated T cells and PD-L1 produced by cancer 67 
cells, a signalling process that would normally prevent T lymphocytes from attacking tumors. 68 
While therapy with ICIs such as nivolumab has substantially improved cancer survival, 69 
increased attention has been called to immune-related adverse events associated with their use 70 
including endocrine autoimmunity (1, 2). ICI-induced autoimmune endocrinopathies involving 71 
the pituitary and thyroid are frequent being reported in up to 10% of patients treated with 72 
antibodies against CTLA-4 or PD-1/PD-L1 (1-5). In contrast, primary adrenal insufficiency and 73 
type 1 diabetes are uncommon (1-3), while ICI-induced autoimmune involvement of the 74 
parathyroid gland is exceedingly rare (4). To date, there have been two reported cases of ICI-75 
induced hypocalcemia, but the etiology of their low calcium levels was not reported (6).  76 
A common cause of hypocalcemia is hypoparathyroidism. Normally, low blood calcium 77 
concentrations are detected by the parathyroid-expressed calcium-sensing receptor (CaSR), 78 
which responds by stimulating parathyroid hormone (PTH) secretion from the parathyroid 79 
glands (7). There is a resulting normalization of serum calcium as it is reabsorbed by the 80 
kidneys, released by bone, and absorbed by the intestine. However, in circumstances of absent, 81 
reduced or ineffective PTH, this regulatory function is lost and hypocalcemia ensues. 82 
Hypoparathyroidism can be due to surgical or autoimmune destruction of the parathyroid glands 83 
(8). In addition, autoantibodies that stimulate CaSR activity, even when blood calcium levels are 84 
lower than normal, can cause the inhibition of PTH secretion from the parathyroid, such that 85 
calcium remains below the critical concentration that would normally stimulate PTH secretion 86 
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(9). Such CaSR-activating autoantibodies have been identified in patients with idiopathic 87 
hypoparathyroidism and autoimmune polyendocrine syndrome type 1 (APS1), in which 88 
hypoparathyroidism is a prominent manifestation (10, 11).  89 
The aims of this study were to describe a patient with a two-year history of metastatic small cell 90 
lung cancer (SCLC), who had been treated with nivolumab a few months prior to presentation 91 
and developed the signs and symptoms of severe hypocalcemia and hypoparathyroidism, and 92 
to investigate a possible autoimmune HWLRORJ\RIWKHSDWLHQW¶Vhypoparathyroidism by testing for 93 
the presence of CaSR autoantibodies. In addition, NALP5 and cytokine autoantibodies were 94 
evaluated since these are indicative of APS1.  95 
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Materials and Methods 96 
Case description  97 
A 61-year-old woman with metastatic SCLC was admitted to our hospital with persistent 98 
nausea, vomiting, epigastric pain, constipation and generalized weakness in July 2017. In 99 
addition to these symptoms, she also reported bilateral distal lower limbs paresthesias but no 100 
muscle spasms or cramps. She had three prior admissions at other institutions within the last 101 
two months for similar symptoms. Low serum calcium levels were the most notable laboratory 102 
finding during these prior hospital admissions. 7KHSDWLHQW¶VK\SRFDOFHPLDZDV WUHDWHGGXULQJ103 
these hospitalizations, and the patient was instructed to take over-the-counter calcium and 104 
vitamin D3 supplementation at discharge. She was not taking the recommended calcium and 105 
vitamin D supplementation at the time of admission to our hospital. 106 
The patient was diagnosed with SCLC in July 2015, which was initially treated with multiple 107 
cycles of platinum-based chemotherapy and radiation therapy. Given the progression of the 108 
disease despite the initial treatment, nivolumab therapy was begun in March 2017. The patient 109 
received six intravenous infusions of nivolumab, which led to partial remission of her SCLC.  110 
The last infusion of nivolumab was two months prior to the current hospitalization.  111 
At our hospital, the patient reported no family history of autoimmune endocrinopathies, neck 112 
irradiation or neck surgery. Her physical examination was unremarkable except for mild gait 113 
ataxia. Chvostek and Trousseau signs were negative. Laboratory findings upon admission are 114 
summarized in Table 1 and showed low total serum calcium, ionized calcium, and PTH levels. A 115 
CT scan of her neck, chest and abdomen revealed a primary left lung mass with extensive 116 
lymph nodes and bone metastases without any identifiable lesions in the parathyroid glands.  117 
During the current hospitalization, her serum calcium level normalized after she received 118 
intravenous calcium gluconate infusions. The patient experienced marked improvement in her 119 
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symptoms following normalization of serum calcium. Magnesium sulfate was infused to treat 120 
hypomagnesaemia. Serum PTH levels remained persistently suppressed despite normalization 121 
of serum calcium and magnesium (Fig. 1). Treatment with oral calcium carbonate and calcitriol 122 
was started as maintenance therapy for hypocalcemia. At two weeks following discharge from 123 
the hospital and continued treatment with calcium and calcitriol, her serum calcium was normal. 124 
However, her serum PTH level remained persistently low.  125 
Due to the terminal nature of her disease and the inconvenience of additional medical 126 
appointments, the patient decided on regularly scheduled follow-ups only with her oncologist at 127 
another institution. We called the patient and her oncologist, learning that nivolumab therapy 128 
was replaced with a different chemotherapy regimen in March 2018 due to progression of 129 
mesenteric nodal metastatic disease. 7KHRQFRORJLVWUHSRUWHGWKDWWKHSDWLHQW¶VVHUXPFDOFLXP130 
was low in March 2018 after the patient stopped taking calcitriol for a few days. Given the nature 131 
of her illness, the patient was reluctant to obtain regular laboratory testing. 132 
Written consent was obtained from the patient for blood tests and publication. 133 
Measurement of CaSR-binding antibodies 134 
CaSR immunoprecipitation assays for detecting CaSR antibodies were carried out as before 135 
(12 7KH SDWLHQW¶V VHUXP DQG KHDOWK\ FRQWURO VHUD n = 10) were stored at -80°C. Human 136 
embryonic kidney 293 (HEK293) cells were transiently transfected with plasmid pcCaSR-FLAG, 137 
and cell extracts were prepared containing expressed CaSR-FLAG protein (11). Aliquots (50-ȝO138 
of GammaBind® Sepharose beads (Amersham Biosciences, Little Chalfont, UK) were mixed 139 
with patient serum, control sera or positive control anti-CaSR antiserum (Alpha Diagnostic 140 
International, San Antonio, TX) in duplicate at 1:100 dilution in 1 ml of immunoprecipitation 141 
buffer and incubated for 1 h at 4°C. The bead/IgG complexes were collected by centrifugation 142 
and incubated with cell extract containing CaSR-FLAG protein at 4°C for 16 h. The 143 
bead/IgG/protein complexes were collected by centrifugation, washed, denatured, and 144 
8 
 
subjected to SDS-PAGE in 7.5% polyacrylamide gels. The separated proteins were transferred 145 
onto Trans-Blot® Transfer Membranes (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK) 146 
using standard protocols. Immunoprecipitated CaSR-FLAG protein was detected using anti-147 
FLAG® M2-Peroxidase Conjugate (Sigma-$OGULFK3RROH8.DQGDQ(&/:HVWHUQ%ORWWLQJ148 
Analysis System (Amersham Biosciences) with a final exposure to pre-flashed x-ray film for 5 149 
min. Densitometry of the developed films was performed in a Bio-Rad GS 690 Scanning 150 
Densitometer with Multi-Analyst Version 1.1 Software (Bio-Rad Laboratories Ltd.), which 151 
produced a densitometry value for each individual band. A CaSR antibody index for each serum 152 
sample in the immunoprecipitation assay was calculated as the densitometry value of the tested 153 
serum/mean densitometry value of 10 control sera. The upper normal limit for the assay was 154 
calculated using the mean CaSR antibody index + 3 SD of these control individuals. A CaSR 155 
antibody index above the upper normal limit was designated as positive for CaSR antibody 156 
reactivity. All assays were run blinded to avoid operator bias. 157 
Measurement of CaSR-activating antibodies 158 
As detailed elsewhere (11), the response of the CaSR to Ca2+ was assessed in HEK293 cells 159 
stably expressing the receptor (HEK293-CaSR) by measuring intracellular inositol-1-phosphate 160 
(IP1) accumulation using an IP-One ELISA Kit (CIS Bio International, Gif-sur-Yvette, France). 161 
Monolayer HEK293-CaSR cells were cultured in 24-well plates. The cells were washed with 162 
serum-free medium and then Ca2+-free assay buffer containing 10 mM lithium chloride. For 163 
investigating antibody effects, cells were pre-incubated for 10 min at 37°C with duplicate IgG 164 
VDPSOHVLQDVVD\EXIIHUZKLFKKDGEHHQSUHSDUHGIURPWKHSDWLHQW¶VDQGFRQWUROVHUDQ 165 
= 10) by standard methods (11). Assay buffer containing varying concentrations of calcium 166 
chloride (0-5 mM final concentration) was added to the cells followed by incubation for 60 min at 167 
37°C. HEK293-CaSR cells without pre-incubation with IgG were also included in experiments as 168 
controls. )ROORZLQJ LQFXEDWLRQFHOOVZHUH O\VHG IRUPLQDW&ZLWKȝORI ,3-One 169 
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ELISA Kit Lysis Reagent (CIS Bio International). The accumulation of intracellular IP1 was 170 
measured according to an IP-One ELISA Kit, an immunoassay based on competition between 171 
free IP1 and IP1-horse-radish peroxidase (HRP) conjugate for binding to anti-IP1 monoclonal 172 
antibody. The results for IP1 accumulation were expressed as: percentage inhibition of IP1-HRP 173 
binding = [1 - IP1-HRP binding in stimulated cells/IP1-HRP binding in unstimulated cells] x 100. 174 
Increasing IP1 accumulation in the HEK293-CaSR cells is reflected by an increase in the 175 
percentage inhibition of IP1-HRP binding. 176 
Measurement of NALP5 antibodies 177 
A TnT® T7-Coupled Reticulocyte Lysate System (Promega, Southampton, UK) was used to 178 
produce [35S]-labelled NALP5 protein in vitro from the transcription-translation of NALP5 cDNA 179 
in plasmid pCMV6-XL5-NALP5 (a gift from Professor Olle Kampe, University Hospital, Uppsala 180 
8QLYHUVLW\8SSVDOD6ZHGHQDVGHWDLOHG LQ WKHPDQXIDFWXUHU¶VSURWRFRO5DGLROLJDQGELQGLQJ181 
assays (RLBA) were carried out as detailed elsewhere (13). In brief, for each RLBA, an aliquot 182 
of NALP5 in vitro transcription-translation reaction containing 100,000 counts per minute (cpm) 183 
of trichloroacetic acid-precipitable material, as determined per WKHPDQXIDFWXUHU¶V LQVtructions, 184 
ZDV VXVSHQGHG LQ  ȝO RI ,3 EXIIHU  P0 7ULV-hydrochloride, pH 8.0, 150 mM sodium 185 
chloride, 1% Triton X-100, and 10 mg/ml aprotinin (Bayer, Newbury, UK)). A sample of patient 186 
or healthy control serum was then added to a final dilution of 1:100. Anti-NALP5 polyclonal goat 187 
antibody (Santa Cruz Biotechnology Inc., Dallas, TX) was used at 1:200 a dilution as a positive 188 
control. All serum and antibody samples were tested in duplicate. After overnight incubation at 4 189 
&ȝORISURWHLQ*6HSKDURVH 4 Fast Flow (GE Healthcare Life Sciences, Little Chalfont, 190 
UK), prepared according to the manufacturer, were added followed by incubation for 1 h at 4°C. 191 
Subsequently, the protein G Sepharose-antibody-antigen complexes were collected by 192 
centrifugation and washed six times for 15 min in immunoprecipitation buffer at 4°C. The 193 
complexes were then transferred to 1 ml of Ultima-Gold® XR scintillation fluid (Packard 194 
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Bioscience, Groningen, The Netherlands) and immunoprecipitated cpm evaluated in a Beckman 195 
LS 6500 Multi-Purpose Scintillation Counter (Beckman Coulter, Inc., Fullerton, CA). A NALP5 196 
antibody index for each serum was calculated as: cpm immunoprecipitated by tested 197 
serum/mean cpm immunoprecipitated by 10 healthy control sera. Each serum was tested in 198 
duplicate in two experiments and the mean NALP5 antibody index calculated. The upper limit of 199 
normal for the NALP5 antibody RLBA was calculated using the mean NALP5 antibody index + 200 
3SD of 10 healthy controls. Any serum sample with NALP5 antibody index above the upper limit 201 
of normal was designated as NALP5 antibody-positive. 202 
Measurement of cytokine antibodies 203 
Antibodies against cytokines were detected in enzyme-linked immunosorbent assays (ELISAs) 204 
(14, 15). Interleukin (IL)-22, IL-17A, IL-17F (R and D Systems, Minneapolis, MN), interferon 205 
(IFN)-omega, IFN-alpha2A and IFN-lamda1 (IL-29) (Sigma-Aldrich) were prepared according to 206 
WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV )RU (/,6$V WKH UHTXLUHG F\WRNLQH ZDV GLOXWHG LQ phosphate-207 
buffered saline (PBS) WR  ȝJPO DQG -ȝO VDPSOHV XVHG WR FRDW WKH ZHOOV RI D &RUQLQJ208 
polystyrene 96-well microtitre plate (Bibby Sterilin Ltd., Bargoed, UK). The plates were then 209 
incubated overnight at 4°C. Excess peptide was removed by decanting, and the wells were 210 
blocked with blocking buffer (PBS containing 0.1% Tween-20 and 3% bovine serum albumin) 211 
for 30 min at 37°C. Plates were washed four times with washing buffer (PBS containing 0.1% 212 
Tween-20). Aliquots (100 µl) of serum at a 1:100 dilution in blocking buffer were added to the 213 
wells. PBS was applied as a control. The plates were incubated at room temperature for 1 h and 214 
then washed four times with washing buffer. Aliquots (100 µl) of anti-human IgG alkaline 215 
phosphatase-conjugate (Sigma-Aldrich) diluted to 1:2000 in blocking buffer were added to the 216 
wells for 1 h at room temperature. After washing five times with washing buffer, 100 µl of 217 
alkaline phosphatase substrate Sigma Fast p-Nitrophenyl Phosphate (Sigma-Aldrich) were 218 
applied to each well and plates incubated at room temperature to allow colour development. A 219 
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LabSystems Integrated EIA Management System (Life Sciences International, Basingstoke, 220 
UK) was used to read absorption of the wells at 405 nm. All sera were tested in duplicate and 221 
the average OD405 value taken. The binding reactivity of each patient and control sera to each 222 
cytokine was expressed as an antibody index calculated as:  mean OD405 of tested serum/mean 223 
OD405 of 10 healthy control sera. Each serum was tested in two experiments and the mean 224 
antibody index calculated. The upper limit of normal for each ELISA was calculated using the 225 
mean antibody index + 3SD of 10 healthy control sera. Patient sera with an antibody index 226 
greater than the upper limit of normal were regarded as positive for cytokine antibodies. 227 
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Results 228 
'HWHFWLRQRI&D65DXWRDQWLERGLHVLQWKHSDWLHQW¶VVHUXP 229 
Initially, a CaSR immunoprecipitation assay, as detailed in Materials and Methods, was used to 230 
analyse WKHSDWLHQW¶VVHUXPIRUCaSR autoantibodies. The upper limit of normal for the CaSR 231 
immunoprecipitation assay was estimated as a CaSR antibody index of 2.81, calculated from a 232 
population of 10 healthy control sera (Fig. 2). The serum sample from the patient tested positive 233 
for CaSR autoantibodies with a CaSR antibody index of 40.1 (Fig. 2). The positive control anti-234 
CaSR antiserum had a CaSR antibody index of 20.5 (Fig. 2). 235 
Subsequently, the response to Ca2+ of the CaSR expressed in HEK293 cells was assessed by 236 
measuring intracellular IP1 accumulation as described in Materials and Methods. To determine 237 
the effects of IgG from the patient and healthy controls (n = 10) on the response of the CaSR to 238 
Ca2+, HEK293-CaSR cells were incubated with IgG samples at a 1:100 dilution prior to no 239 
stimulation or stimulation with a range of Ca2+ concentrations (0.5, 1.5, 3.0, and 5.0 mM). Each 240 
experiment included HEK293-CaSR cells stimulated with Ca2+ alone. IP accumulation was 241 
measured using the IP-One ELISA Kit as detailed in Materials and Methods and the percentage 242 
inhibition of IP1-HRP binding was calculated. 243 
Of the 10 control IgG samples analyzed, none had any effect upon the levels of IP1 244 
accumulation when compared with stimulation by Ca2+ alone (Fig. 3). In contrast, the IgG 245 
sample from the patient significantly increased the levels of IP1 accumulation at Ca2+ 246 
concentrations of 0.5, 1.5 and 3.0 mM when compared with Ca2+-stimulation alone (P values < 247 
0.001, one-way ANOVA) (Fig. 3). The IgG from the patient had no detectable effect on IP1 248 
accumulation, however, when no Ca2+ was added to the buffer, indicating that some degree of 249 
receptor activation by its natural ligand, Ca2+, was needed to see the functional effect of the IgG. 250 
The results indicated the presence of CaSR-stimulating activity in the patient IgG sample.  251 
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Detection of NALP5 and cytokine autoantibodies LQWKHSDWLHQW¶VVHUXP 252 
7KH SDWLHQW¶V VHUXP VDPSOH was evaluated for NALP5 and cytokine antibodies using RBLAs 253 
and ELISAs, respectively, as detailed in Materials and Methods. The upper limits of normal for 254 
antibody assays against IL-22, IL-17F, IL-17A, IFN-omega, IFN-alpha2A, and IFN-lamda1, and 255 
NALP5 were antibody indices of 1.29, 1.25, 1.33, 1.89, 2.03, 1.70, and 1.81, respectively. The 256 
patient was negative for autoantibodies against NALP5 and all the cytokines tested; antibody 257 
indices were 1.01, 0.98, 0.91, 0.75, 1.02, 1.11, and 1.07 for assays measuring autoantibodies 258 
against IL-22, IL-17F, IL-17A, IFN-omega, IFN-alpha2A, and IFN-lamda1, and NALP5, 259 
respectively.  260 
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Discussion  261 
The biochemical investigations carried out here strongly suggest hypoparathyroidism as the 262 
FDXVH RI WKH SDWLHQW¶V hypocalcemia. As there was no history of neck radiation, surgery or 263 
infiltration of the parathyroids on imaging, an autoimmune etiology of hypoparathyroidism 264 
seemed most likely. Furthermore, persistently low PTH despite normalization of serum 265 
magnesium excluded the possibility of hypomagnesemia as the cause of hypocalcemia and 266 
hypoparathyroidism. 267 
Although the parathyroid glands are not the target of most autoimmune diseases, autoimmunity 268 
is an important cause of hypoparathyroidism, either as an isolated endocrinopathy or as a 269 
component of APS1 (16, 17). Autoimmune hypoparathyroidism can be caused by permanent 270 
hypoparathyroidism owing to irreversible, immune-mediated damage to the parathyroid glands 271 
or functional hypoparathyroidism due to antibody-induced activation of signaling pathway(s) 272 
regulating parathyroid function (18). In APS1, common autoantibody targets include parathyroid-273 
expressed NALP5 and cytokines. However, testing carried out here revealed that the patient 274 
was not positive for autoantibodies against NALP5, a marker for parathyroid autoimmunity, or a 275 
panel of interferons and interleukins which are diagnostic for APS1 (13-15). As such, the patient 276 
was not diagnosed with multiple endocrine autoimmune disease to account for her low 277 
parathyroid function. Autoantibodies directed against the parathyroid-expressed CaSR have 278 
been recognized to be present in the serum of patients with autoimmune hypoparathyroidism 279 
(16), including autoantibodies that can activate the receptor, thereby causing reduced PTH 280 
secretion (10, 11). 281 
Antibody tests of WKHSDWLHQW¶VVHUXPFRQILUPHGRXUGLDJQRVLVRf hypoparathyroidism caused by 282 
the development of CaSR-activating autoantibodies. Autoantibody-activation of the CaSR was 283 
indicated by increased inositol-1-phosphate levels in a cell line expressing the CaSR following 284 
WUHDWPHQWZLWKWKHSDWLHQW¶V,J*WKHphosphoinositide pathway being a key intracellular mediator 285 
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of CaSR activation. Thus, by shifting the calcium-PTH curve to the left and decreasing the set-286 
point of the CaSR, PTH is not released at lower serum calcium concentrations resulting in 287 
hypocalcemia. The temporal relationship between the initiation of nivolumab infusions suggests 288 
that this drug is likely responsible for the development of the CaSR-activating autoantibodies, 289 
although was cannot rule out with certainty that the development of anti-CaSR antibodies and 290 
hypoparathyroidism were coincidental. $OWKRXJK WKH SDWLHQW¶V K\SRSDUDWK\URLGLVP appears 291 
persistent despite discontinuation of nivolumab, it is possible that improvement could take place 292 
with longer follow-up. To the best of our knowledge this is the first report illustrating a case of 293 
autoimmune hypoparathyroidism induced by ICI-blockade as the underlying cause.   294 
The reasons for differential autoimmune involvement of the endocrine glands between anti-PD1 295 
and anti-CTLA-4 therapy are not entirely clear (2). Higher risk of hypophysitis with anti-CTLA-4 296 
therapy such as ipilimumab compared to anti-PD1 pembrolizumab may be due to the 297 
expression of CTLA-4 in the normal pituitary gland (2). In contrast to the high risk of 298 
hypophysitis with anti-CTLA-4 therapy, autoimmune thyroiditis appears to be more common in 299 
anti-PD1 therapy. It has been speculated that in addition to effects on T cell immunity, anti-PD1 300 
therapy may augment humoral immunity, thus boosting anti-thyroid antibody formation (2). 301 
Careful studies of ICIs in vitro and in animal models have also shown that their complex role in 302 
T cell immunity and blockade may involve the inhibition of regulatory T cells, which could be a 303 
factor in the induction of autoimmunity (19). 304 
Given the high risk of autoimmune diseases, including endocrinopathy, during treatment with 305 
ICIs, the risk of toxicity should always be balanced against the benefit that may derive from the 306 
ICI-blockade. As ICIs are now used to treat many cancers, clinicians should be aware of the 307 
potential risk for hypocalcemia associated with their use.  308 
 309 
 310 
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Figure Legends 376 
Figure 1. Time course for changes in biochemical laboratory tests.  7KHSDWLHQW¶VLonized 377 
calcium, magnesium, and PTH levels during admission to our hospital are shown. The normal 378 
range is indicated by the hatched boxes: ionized calcium, 1.12-1.31 mmol/L; magnesium, 1.62-379 
2.62 mg/dL; and PTH, 12-65 pg/mL. 380 
Figure 2. Detection of patient CaSR autoantibodies. Serum from the patient, healthy controls 381 
(n = 10), and positive control anti-CaSR antiserum were tested in CaSR immunoprecipitation 382 
assays at a 1:100 dilution and assigned a CaSR antibody index as detailed in Materials and 383 
Methods. The upper limit of normal for the CaSR immunoprecipitation assay was calculated 384 
using the mean CaSR antibody index + 3 SD of 10 control sera, which gave a CaSR antibody 385 
index value of 2.81. A CaSR antibody index above the upper normal limit was designated as 386 
positive for anti-CaSR antibody reactivity. 7KH &D65 DQWLERG\ LQGH[ RI WKH SDWLHQW¶V VDmple 387 
(40.1) and the positive control anti-CaSR antiserum (20.5) are shown and are positive. 388 
Figure 3. Effect of patient IgG on CaSR activity. Intracellular IP1 accumulation in HEK293-389 
CaSR cells was measured in response to Ca2+-stimulation (final concentrations of 0-5 mM) after 390 
cells were pre-incubated with WKHSDWLHQW¶V,J*VDPSOHRUKHDOWK\FRQWURO,J*DWDGLOXWLRQ391 
Cells without pre-incubation with IgG were also included. The accumulation of intracellular IP1 392 
was measured using an IP-One ELISA Kit, an immunoassay based on competition between free 393 
IP1 and IP1-horse-radish peroxidase (HRP) conjugate for binding to anti-IP1 monoclonal 394 
antibody. The results for IP1 accumulation were expressed as: percentage inhibition of IP1-HRP 395 
binding = [1 - IP1-HRP binding in stimulated cells/IP1-HRP binding in unstimulated cells] x 100. 396 
Increasing IP1 accumulation in the HEK293-CaSR cells is reflected by an increase in the 397 
percentage inhibition of IP1-HRP binding. The results show IP1 accumulation (mean ± SD of six 398 
experiments) in Ca2+-stimulated HEK293-CaSR cells that were pre-incubated with either IgG 399 
from the patient or IgG from a single control, or that were not pre-incubated with IgG. Only the 400 
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SDWLHQW¶V,J*VDPSOHVLJQLILFDQWO\LQFUHDsed the levels of IP1 accumulation when compared with 401 
Ca2+-stimulation (at 0.5, 1.5, and 3 mM) of HEK293-CaSR cells not pre-incubated with IgG: *P 402 
values were < 0.001 (One-way ANOVA).  403 
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Table 1. Laboratory Test Results Upon Admission to Our Hospital 
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 409 
 410 
 411 
 412 
 413 
 414 
 415 
 416 
 417 
 418 
 
  
 
 
 
 
  
Test Results  Normal range 
Calcium 5.8 mg/dL (Low) 8.3-10 mg/dL 
Albumin 4.2 g/dL (Normal) 3.6-4.8 g/dL 
Ionized calcium 0.85 mmol/L (Low) 1.12-1.32 mmol/L 
PTH 7.77 pg/mL (Low) 12-65 pg/mL 
Magnesium 1.4 mg/dL (Low 1.6-2.6 mg/dL 
Potassium 3.4 mEg/L (Low) 3.6-5.6 mEq/L 
Phosphate 4.3 mg/dL (Normal) 2.5-4.5 mg/dL 
25-hydroxy vitamin D 23.8 ng/mL (Low) 30-200 ng/mL 
1,25-dihydroxy vitamin D 10.6 pg/mL (Low) 19.9-79.3 pg/mL 
TSH 0.99 mlU/mL (Normal) 0.45-4.5 mIU/mL 
EKG-QTc 492 sec (High) 431-470 sec (women) 
22 
 
Figure 1 
 
 
 
 
  
23 
 
Figure 2 
 
 
 
 
 
 
 
  
24 
 
Figure 3 
 
 
 
 
 
